Aleve and Pentasa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aleve (naproxen sodium) and Pentasa (mesalamine). Common drug interactions include pneumonia among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Aleve and Pentasa. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Aleve?

Aleve has active ingredients of naproxen sodium. It is often used in pain. eHealthMe is studying from 70,279 Aleve users. Check the latest studies of Aleve.

What is Pentasa?

Pentasa has active ingredients of mesalamine. It is often used in crohn's disease. eHealthMe is studying from 23,325 Pentasa users. Check the latest studies of Pentasa.



On Jul, 31, 2026

39 people who take Aleve and Pentasa together, and have interactions are studied.

Aleve and Pentasa drug interactions.

What are the common drug interactions of Aleve and Pentasa, by gender? *:

female:

  1. Pneumonia
  2. Hepatic enzyme increased
  3. Influenza
  4. Dyspnoea (difficult or laboured respiration)
  5. Abdominal pain
  6. Abortion spontaneous (naturally occurring miscarriage)
  7. Blindness unilateral
  8. Diarrhoea
  9. Injection site haemorrhage (bleeding from injection site)
  10. Injection site pain

male:

  1. Dyspnoea (difficult or laboured respiration)
  2. Arthralgia (joint pain)
  3. Cough
  4. Dizziness postural
  5. Drug hypersensitivity
  6. Dyspnoea at rest (difficult or laboured breathing during rest)
  7. Dyspnoea exertional (breathlessness or shortness of breath)
  8. Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)
  9. Haemorrhage (bleeding)
  10. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)

What are the common drug interactions of Aleve and Pentasa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Blindness unilateral
  2. Abdominal pain
  3. Blindness transient (sudden loss of vision)
  4. Drug ineffective
  5. Euphoric mood (excessively happy but may become angry or irritable)
  6. Injection site pain
  7. Memory impairment
  8. Optic atrophy (the loss of a proportion of optic disc nerve fibres)
  9. Optic neuritis (optic nerve inflammation)
  10. Rash macular (small, flat red spots)

40-49:

  1. Abortion spontaneous (naturally occurring miscarriage)
  2. Anxiety
  3. Asthenia (weakness)
  4. Chronic kidney disease
  5. Disease progression
  6. Hepatic enzyme increased
  7. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  8. Influenza
  9. Influenza like illness
  10. Maternal exposure during pregnancy (use of substance during pregnancy)

50-59:

  1. Haematochezia (passage of stools containing blood)
  2. Abdominal distension
  3. Alopecia (absence of hair from areas of the body)
  4. Dyspnoea (difficult or laboured respiration)
  5. Haemoglobin decreased
  6. Heart rate increased
  7. Large intestinal ulcer haemorrhage (bleeding from large intestine ulcer)
  8. Miosis (constriction of the pupil of the eye, resulting from a normal response to an increase in light)
  9. Ocular hyperaemia (an abnormally large amount of blood in eye)
  10. Onychoclasis (breaking of the nails)

60+:

  1. Dyspnoea (difficult or laboured respiration)
  2. Arthralgia (joint pain)
  3. Diarrhoea
  4. Dyspnoea at rest (difficult or laboured breathing during rest)
  5. Epistaxis (bleed from the nose)
  6. Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)
  7. Intervertebral disc disorder (spinal disc disorder)
  8. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  9. Nephrolithiasis (calculi in the kidneys)
  10. Neuropathy peripheral (surface nerve damage)

What are the existing conditions these people have? *

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 4 people, 10.26%
  2. Joint Pain: 4 people, 10.26%
  3. Diabetes: 4 people, 10.26%
  4. Depression: 4 people, 10.26%
  5. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 10.26%
  6. Hypersensitivity: 3 people, 7.69%
  7. Diarrhea: 3 people, 7.69%
  8. Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 2 people, 5.13%
  9. Seasonal Allergy (allergic condition due to certain season): 2 people, 5.13%
  10. Nausea (feeling of having an urge to vomit): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Aleve and Pentasa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Aleve and Pentasa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Aleve:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pentasa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Aleve and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentasa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on naproxen sodium and mesalamine (the active ingredients of Aleve and Pentasa, respectively), and Aleve and Pentasa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: